title: Development of biodegradable microcapsules as carrier for oral controlled delivery of amifostine.
abstract: The primary objective of this project was to develop a biodegradable, orally active controlled-release formulation of amifostine. Development of such a formulation will mark an important advancement in the areas of chemoprotection and radioprotection. Biodegradable microcapsules of amifostine were prepared using poly(lactide/glycolide) (PLGA 50:50). The microcapsules were prepared by solvent evaporation technique. Amifostine-loaded microcapsules were evaluated for particle size, surface morphology, thermal characteristics, and drug release. Particle size and surface morphology were determined using scanning electron microscopy (SEM). Thermal characterization was conducted using differential scanning calorimetry (DSC). In vitro release study was performed at 37 degrees C using phosphate buffer (pH 7.4). Amifostine release was calculated by measuring the amount of drug remaining within the microcapsules at a specific sampling time. The amount of amifostine in the samples was determined by high-performance liquid chromatography (HPLC) using an electrochemical detector. The yield of microcapsules was 75%. Scanning electron microscopy pictures revealed that the particles were nearly spherical and smooth with an average size of 54 microm. Differential scanning calorimetry thermograms showed that microcapsules loaded with amifostine have a glass transition at 39.4 degrees C, and the melting endotherm of amifostine was absent. The absence of a melting endotherm for amifostine was an indication that amifostine was not in the crystalline state in the microcapsules, but rather in the form of a solid solution in PLGA. Approximately 50% amifostine was released during the first 6 hr of the in vitro release study. The drug, however, continued to release over the observed period of 12 hr during which 92% amifostine was released.
authors.affiliation: College of Pharmacy, Xavier University of Louisiana, New Orleans 70125, USA. tmandal@xula.edu
authors.forename: T K
authors.initials: TK
authors.lastname: Mandal
authors.forename: L A
authors.initials: LA
authors.lastname: Bostanian
authors.forename: R A
authors.initials: RA
authors.lastname: Graves
authors.forename: S R
authors.initials: SR
authors.lastname: Chapman
authors.forename: I
authors.initials: I
authors.lastname: Womack
mesh_terms: D000284:Administration, Oral; D004999:Amifostine / Q000737:chemistry*; D002214:Capsules; D004337:Drug Carriers; D016503:Drug Delivery Systems / Q000379:methods*; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D002214:Capsules; D004337:Drug Carriers; D004999:Amifostine